Are you looking for a stock?

Try one of these

News Tagged By: Pharmaceuticals

Allergan said to be in active takeover talks with Actavis
Allergan Inc., the Botox maker seeking to fend off a hostile takeover by Valeant Pharmaceuticals International Inc., is in active talks with Actavis Inc. on a potential alternative deal, people with knowledge of the matter said.
Posted on 11-06-2014 at 10:40 AM
AbbVie board ditches planned $55 billion Shire acquisition
U.S. drugmaker AbbVie has pulled the plug on its plan to buy Dublin-based Shire, recommending shareholders vote against the planned $55 billion takeover following new U.S. tax rules.
Posted on 10-16-2014 at 7:09 AM
Is Tekmira more valuable than its Ebola drug?
Shares of Vancouver-based Tekmira Pharmaceuticals Corp. shot up 45 percent last Friday on the news that the U.S. Food and Drug Administration (FDA) would remove regulatory roadblocks preventing their TKM-Ebola drug from being administered to those infected with the deadly virus in West Africa.
Posted on 8-11-2014 at 2:15 PM
Weak guidance puts Valeant's growth prospects, Allergan bid, in doubt: Piper Jaffray
Is Valeant Pharmaceuticals International Inc. throwing a wrench into the company’s growth by acquisition machine over its drawn-out public battle to acquire Botox-maker Allergan Inc.?
Posted on 7-31-2014 at 11:59 AM
AbbVie to buy Shire for $54.8B for tax benefit
AbbVie Inc. agreed to buy Shire Plc for about 32 billion pounds ($54.8 billion US), becoming the latest U.S. health-care company to shift its tax residence abroad in a record surge in industry deals.
Posted on 7-18-2014 at 8:24 AM
Valeant looks for acquisitions to dodge taxes: Melnyk
This is the motive behind Valeant Pharmaceuticals International’s private equity-esq growth by acquisition strategy according to Biovail Corp. founder Eugene Melnyk.
Posted on 7-15-2014 at 4:17 PM
When it comes to Valeant and Allergan, why not bet on both?
Valeant and hedge fund manager Bill Ackman continued their pursuit of botox maker Allergan this week. On Monday, Ackman’s hedge fund Pershing Square unveiled his slate of directors for Allergan’s board. And while much has been made about how the deal may play out, according to Galiant Capital’s President and CEO Ian Shaffer, both stocks might be a good buy.
Posted on 7-11-2014 at 5:04 PM
Today's Guests CTV Two CTV News CTV News Channel BNN - Business News Network CP24